Lymphadenopathy resident survival guide
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Javaria Anwer M.D.[2]
Synonyms and keywords: lymphadenopathy management guide, lymph node pathology management guide
Lymphadenopathy resident survival guide microchapters |
---|
Overview |
Causes |
Management |
Do's |
Don'ts |
Overview
Lymphadenopathy (LAD) is used to describe abnormal size, consistency, and the number of lymph nodes. Under normal conditions, lymph nodes may not be palpated. The lymph nodes maybe central or peripheral located deep in the subcutaneous tissue. Common causes of lymphadenopathy include infectious and non-infectious. A thorough physical exam is important to establish a differential diagnosis. The common causes of lymphadenopathy can be remembered using pneumonic CHICAGO (Cancer, Hypersensitivity, Infection, Connective tissue disorders, Atypical lymphoproliferative disorders, Granulomatous, and Others). Excisional biopsy is the gold standard for tissue diagnosis. Infections can be treated with antibiotics while cancers require surgical resection, staging and chemotherapy or radiotherapy.
Causes
Life Threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- Infectious mediastinal lymphadenopathy[1]
Common Causes
The American Academy of Family Physicians (AAFP) and many research articles utilize a pneumonic CHICAGO to include all causes of lymphadenopathy based on etiology.[2][3] The causes may also be remembered based on the location of lymph nodes.
- Cancers:
- Hypersensitivity :
- Serum sickness, immunization reactions, graft-vs-host disease, silicone allergy, and drug allergy (such as sulfonamides, allopurinol, carbamazepine, etc).
- Infections:
- Fungal, Protozoan, Rickettsial (Typhus), Helminthes.
- Bacterial: Tiberculosis, syphilis (primary and secondary), chancroid, staphylococcus or streptococcal skin infections.
- Viral: IM, CMV, HIV,lymphadenitis post vaccination, adenovirus, herpes zoster, and hepatitis (infectious), and melioidosis.
- Chlamydial (lymphogranuloma venereum), protozoan (toxoplasmosis), mycotic (histoplasmosis, coccidioidomycosis, helminthic (filariasis, and rickettsial (typhus).
- Connective tissue disorders:
- Atypical lymphoproliferative disorders :
- Granulomatous:
- Others:
- Rosai Dorfman disease, Kikuchi disease, pseudotumor of L.N, transformation of germinal centers, and vascular transformation of sinuses.
- For more detailed information in the causes of lymphadenopathy, click here.
Management
Diagnostic algorithm and management
Abbreviations: UVUltraviolet rays; UTIUrinary tract infection; HEENT: Head, Eyes, Ears. Nose, and Throat exam; IM: Infectious Mononucleosis; L.N: Lymph node;CBC: Complete blood count; ESR: Erythrocyte sedimentation rate; CMP: Comprehensive metabolic panel; LFTs:Liver function tests; URTI: Upper respiratory tract infection; CMV: Cytomegalovirus; IgM: Immuniglobulin M; IgG:Immunoglobuin G; ANA:Antinuclear antibodies; CXR:Chest X-ray; CT: CT scan; VDRL: Venereal disease research laboratory; RPR:Reactive plasma reagen
The algorithm illustrates the approach to management of lymphadenopathy[4][5][6][7][8]. Borrowed from:[9][10][11]
.History
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Physical exam Appearance of the patient Cachexia or surgical scar marks demonstrating previous malignancy treatment
❑ HEENT
❑ Extremities exam | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Palpable lymph node ❑ Location: (Localized vs generalized)
❑ Dimensions
❑ Tenderness or pain:
❑ Consistency
❑ Mobility
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Labs ❑ CBC with differential
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnostic of self-limiting or benign disease Pharyngitis, URTI, conjunctivitis, cat-scratch disease, etc | Suggests infection/ serious infection | Unexplained | Suggests malignancy | ||||||||||||||||||||||||||||||||||||||||||||||||||
May require specific tests | Perform specific tests ❑ IM: Heterophile Antibody and monospot test | Risk factors for malignancy Family history, age, exposure, etc | Perform specific tests | ||||||||||||||||||||||||||||||||||||||||||||||||||
Excisional biopsy | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Positive | Negative | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Negative | Positive | ||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Treat ❑ To read about the treatment of strept throat, click here | Staging | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Treat | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Low risk | High risk | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Specific tests/ biopsy | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Localized | Generalized | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Review history and clues suggesting malignancy | Review history and clues suggesting malignancy | Positive | Treat | ||||||||||||||||||||||||||||||||||||||||||||||||||
Negative | |||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Specific tests such as CXR, ultrasound, CT, lab workup, biopsy. ❑ The US findings that help differentiate benign LAD from malignant include:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Observe 3-4 weeks | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Undiagnostic | Diagnostic | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Progress/persists | Regress | ||||||||||||||||||||||||||||||||||||||||||||||||||||
No follow-up | Biopsy | Treatment | |||||||||||||||||||||||||||||||||||||||||||||||||||
Positive | Negative | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Staging | Follow-up | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Biopsy | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Negative | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Positive | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Staging | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Differential diagnosis and management[10][11][12][13][9]
- For detailed information on the neck lymphadenopathy and its diagnostic findings please click here.
Localised lymphadenopathy
- The table describes possible infectious and oncologic differential diagnoses based upon the location of lymphadenopathy. Please click on the disease name in the management section for a detailed review of the medical therapy utilized in the management of the specific entity. Please click on the disease name in other columns for a detailed review of the disease in general.
Generalized lymphadenopathy
- The table describes possible differential diagnoses of generalized lymphadenopathy based upon the cause. Please click on the disease name in the management section for a detailed review of the medical therapy utilized in the management of the specific entity. Please click on the disease name in other columns for a detailed review of the disease in general.
Autoimmune | Drug reactions | Infections | Malignancies | Storage disorders | Management (click on disease name to read about the treatment) |
---|---|---|---|---|---|
4. Drugs such as sulfonamides, allopurinol, carbamazepine, etc. |
5. Infectious mononucelosis |
|
Staging
- TNM stands for Tumor, Nodes, and Metastasis. The TNM staging system is widely utilized in staging tumors, especially solid tumors. For a detailed review of the TNM staging system please click here.
- For a detailed review of the staging systems utilized in cancer management please click here.
- Ann Arbor staging is utilized to stage lymphomas. Pleaseclick here for a detailed review on the staging system.
Do's
- Patients with immunodeficiency should have a wide differential diagnosis considering non-Hodgkin's lymphoma and Kaposi sarcoma.[11]
- Remember that lymphadenopathy involving supraclavicular L.N poses the highest risk of malignancy (90% among patients >40 years of age) and 25% among < 40 years old. [14]
- Needle aspiration biopsy or excisional biopsy is the gold standard for the tissue diagnosis and evaluation for lymphadenopathy.[9]
- When lymphadenopathy is present, it is important to examine the whole area of lymphatic drainage of the particular organ. For example, examining the region beneath the umbilicus in case of inguinal lymphadenopathy.
Don'ts
- Physical examination should never be missed as a finding may change the course of differential diagnosis. Missing the physical exam may lead to unnecessary investigations and delays.[4]
References
- ↑ Hiraishi Y, Goto Y, Ohishi N, Nagase T (May 2013). "Infectious mediastinal lymphadenopathy after repeated transbronchial needle aspiration". BMJ Case Rep. 2013. doi:10.1136/bcr-2012-007998. PMC 3669807. PMID 23723103.
- ↑ "Tips From Other Journals - American Family Physician".
- ↑ Habermann TM, Steensma DP (July 2000). "Lymphadenopathy". Mayo Clin. Proc. 75 (7): 723–32. doi:10.4065/75.7.723. PMID 10907389.
- ↑ 4.0 4.1 Garg PK, Jain BK, Dubey IB, Sharma AK (2013). "Generalized lymphadenopathy: physical examination revisited". Ann Saudi Med. 33 (3): 298–300. doi:10.5144/0256-4947.2012.01.7.1525. PMC 6078537. PMID 22750769.
- ↑ Soldes OS, Younger JG, Hirschl RB (October 1999). "Predictors of malignancy in childhood peripheral lymphadenopathy". J. Pediatr. Surg. 34 (10): 1447–52. doi:10.1016/s0022-3468(99)90101-x. PMID 10549745.
- ↑ Ghirardelli ML, Jemos V, Gobbi PG (March 1999). "Diagnostic approach to lymph node enlargement". Haematologica. 84 (3): 242–7. PMID 10189390.
- ↑ Ramadas AA, Jose R, Varma B, Chandy ML (2017). "Cervical lymphadenopathy: Unwinding the hidden truth". Dent Res J (Isfahan). 14 (1): 73–78. doi:10.4103/1735-3327.201136. PMC 5356393. PMID 28348622.
- ↑ Wilson, Adrian (2008). "Pharyngitis": 15–24. doi:10.1007/978-1-60327-034-2_2.
- ↑ 9.0 9.1 9.2 Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A (March 2014). "Peripheral lymphadenopathy: approach and diagnostic tools". Iran J Med Sci. 39 (2 Suppl): 158–70. PMC 3993046. PMID 24753638.
- ↑ 10.0 10.1 Ferrer R (October 1998). "Lymphadenopathy: differential diagnosis and evaluation". Am Fam Physician. 58 (6): 1313–20. PMID 9803196.
- ↑ 11.0 11.1 11.2 Bazemore AW, Smucker DR (December 2002). "Lymphadenopathy and malignancy". Am Fam Physician. 66 (11): 2103–10. PMID 12484692.
- ↑ Kiran KU, Krishna Moorthy KV, Meher V, Rao PN (2009). "Relapse of leprosy presenting as nodular lymph node swelling". Indian J Dermatol Venereol Leprol. 75 (2): 177–9. doi:10.4103/0378-6323.48666. PMID 19293508.
- ↑ Bonnetblanc JM, Bédane C (2003). "Erysipelas: recognition and management". Am J Clin Dermatol. 4 (3): 157–63. doi:10.2165/00128071-200304030-00002. PMID 12627991.
- ↑ Fijten GH, Blijham GH (October 1988). "Unexplained lymphadenopathy in family practice. An evaluation of the probability of malignant causes and the effectiveness of physicians' workup". J Fam Pract. 27 (4): 373–6. doi:10.1080/09503158808416945. PMID 3049914.